Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
To turn the smart transmitter ON, press and hold the power button for about five seconds.
- The smart transmitter will vibrate once.
- Release the power button and the LED will blink once indicating the power is ON.
At any time, you can press the power button once to see if the smart transmitter is ON. If the LED appears, the smart transmitter is ON. If no LED appears, the smart transmitter is OFF.
Go to About > My Account to see the email address that was used to log into the mobile app.
The Eversense® E3 Sensor is implanted in the upper arm.
To view the Eversense® CGM user’s Glucose Alert History, swipe your screen to the left from the trend graph.
The Alert History screen will list the last 20 glucose-related alerts that the user received in their Eversense® CGM App.
These alerts monitor events such as the rising or falling of glucose rates as well as low or high, and predicted low or high, glucose values (hypoglycemia or hyperglycemia).
Note: You will only receive predicted high and low glucose alerts if the Eversense® CGM user has predictive alerts enabled.
While the Eversense® E3 Sensor is intended to be removed at end of sensor life, it has undergone biocompatibility testing and meets the requirements of a permanent implant, and therefore it should not cause a biocompatibility concern if left in a patient. However, the sensor will not provide data beyond 180 days and you will need to make arrangements to have it removed.
A compatible smart device is required in order to use the Eversense E3 CGM. Please see our Compatibility page for a list of compatible devices.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
MKT-001692 Rev 1